MedImmune and Micromet have initiated a Phase I trial of MEDI-565 (MT111) in patients with advanced gastrointestinal cancers.
The dose-escalation study is designed to evaluate the safety, tolerability, and anti-tumour activity of the product candidate in adults with advanced gastrointestinal cancers.
Go deeper with GlobalData
Dose escalation in subsequent cohorts will be based on safety and tolerability.
After the maximum tolerated dose is established, additional study subjects with refractory colorectal or pancreatic cancer will be included in a dose-expansion phase to further assess the safety and anti-tumour activity.
MEDI-565 (MT111) is a BiTE antibody designed to direct a patient’s T cells, the body’s most potent killer cells, against cancer cells that express carcinoembryonic antigen.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
